{
    "info": {
        "nct_id": "NCT06011109",
        "official_title": "A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma",
        "inclusion_criteria": "1. Patients must have pathologically proven diagnosis of high grade (aka grade III or IV) glioma that has progressed on bevacizumab (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma, H3K27M mutant glioma).\n2. Patients must have received prior radiation therapy and standard temozolomide. Patients who have received any number of therapies for previous progressions will be considered eligible.\n3. Patients must be three or more months from the end of chemoradiotherapy or have biopsy or imaging consistent with disease progression.\n4. Physiologic Status/Age: Patients must be 19 years of age or older (the age of consent in Nebraska.)\n5. Patients must have recovered from any toxicity of prior therapy to Grade 1 or less.\n6. ECOG Performance Status of 0-3.\n7. Patients must have an adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3).\n8. Patients must have adequate renal and hepatic function with:\n\n   1. creatinine < 1.5 x institutional upper limit of normal (ULN).\n   2. total bilirubin < 1.5 x ULN (unless due to Gilbert's disease)\n   3. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 x ULN\n   4. serum alkaline phosphatase less than 2.5 times the upper limits of normal)\n9. The patient must willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.\n10. Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment.\n11. Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study. (Non-child bearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries).\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
        "exclusion_criteria": "1. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral APG-157, or put the study outcomes at undue risk\n2. Immunotherapy, chemotherapy, radiotherapy, or experimental therapy within one full cycle period before first dose of study drug (i.e., for lomustine 6 weeks, for temozolomide 4 weeks)\n3. Lactating or pregnant\n4. History of uncontrollable allergic reactions to bevacizumab\n5. Clinically Significant Cardiovascular Disease Defined as follows:\n\n   * Inadequately controlled hypertension (i.e., systolic blood pressure (SBP) > 160 mm Hg and/or diastolic blood pressure (DBP) > 90 mm Hg despite antihypertensive therapy)\n   * History of cerebrovascular accident (CVA) within 6 months\n   * Myocardial infarction or unstable angina within 6 months\n6. Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > Grade 3 within 4 weeks prior to registration. Note: Patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks\n7. Active wound, a serious or non-healing wound, an active ulcer or untreated bone fracture within the last two months.\n8. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess ≤ 6 months prior to registration.\n9. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days prior to registration\n10. Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Physiologic Status/Age: Patients must be 19 years of age or older (the age of consent in Nebraska.)",
            "criterions": [
                {
                    "exact_snippets": "Patients must be 19 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 19 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 19 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... <2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) <2.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. ECOG Performance Status of 0-3.",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0-3",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Patients must have an adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3).",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3)",
                    "criterion": "bone marrow reserve",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ANC count ≥1,500/mm3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin > 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count ≥100,000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. creatinine < 1.5 x institutional upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "creatinine < 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients must be three or more months from the end of chemoradiotherapy or have biopsy or imaging consistent with disease progression.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be three or more months from the end of chemoradiotherapy",
                    "criterion": "time since end of chemoradiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy or imaging consistent with disease progression",
                    "criterion": "evidence of disease progression",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "biopsy consistent with disease progression",
                                "imaging consistent with disease progression"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. total bilirubin < 1.5 x ULN (unless due to Gilbert's disease)",
            "criterions": [
                {
                    "exact_snippets": "total bilirubin < 1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless due to Gilbert's disease",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "cause of elevated bilirubin",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. The patient must willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.",
            "criterions": [
                {
                    "exact_snippets": "The patient must willingly provide written, informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients must have pathologically proven diagnosis of high grade (aka grade III or IV) glioma that has progressed on bevacizumab (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma, H3K27M mutant glioma).",
            "criterions": [
                {
                    "exact_snippets": "pathologically proven diagnosis of high grade (aka grade III or IV) glioma",
                    "criterion": "glioma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pathologically proven diagnosis of ... glioma",
                    "criterion": "glioma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on bevacizumab",
                    "criterion": "progression on bevacizumab",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma, H3K27M mutant glioma",
                    "criterion": "glioma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "anaplastic astrocytoma",
                                "anaplastic oligodendroglioma",
                                "glioblastoma",
                                "gliosarcoma",
                                "H3K27M mutant glioma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients must have received prior radiation therapy and standard temozolomide. Patients who have received any number of therapies for previous progressions will be considered eligible.",
            "criterions": [
                {
                    "exact_snippets": "must have received prior radiation therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received ... standard temozolomide",
                    "criterion": "temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients must have adequate renal and hepatic function with:",
            "criterions": [
                {
                    "exact_snippets": "adequate renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential ... must be non-pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of reproductive potential ... must be ... non-nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective barrier method of birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "throughout the study and for up to 6 months following treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patients must have recovered from any toxicity of prior therapy to Grade 1 or less.",
            "criterions": [
                {
                    "exact_snippets": "recovered from any toxicity of prior therapy to Grade 1 or less",
                    "criterion": "toxicity of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. serum alkaline phosphatase less than 2.5 times the upper limits of normal)",
            "criterions": [
                {
                    "exact_snippets": "serum alkaline phosphatase less than 2.5 times the upper limits of normal",
                    "criterion": "serum alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "times the upper limits of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study. (Non-child bearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries).",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study.",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study initiation"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Non-child bearing potential is defined as age 55 years or older and no menses for two years",
                    "criterion": "child-bearing potential (menopausal status by age and menses)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 55,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years since last menses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any age with surgical removal of the uterus and/or both ovaries",
                    "criterion": "child-bearing potential (surgical sterilization)",
                    "requirements": [
                        {
                            "requirement_type": "surgical removal",
                            "expected_value": [
                                "uterus",
                                "both ovaries"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Lactating or pregnant",
            "criterions": [
                {
                    "exact_snippets": "Lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Clinically Significant Cardiovascular Disease Defined as follows:",
            "criterions": [
                {
                    "exact_snippets": "Clinically Significant Cardiovascular Disease",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > Grade 3 within 4 weeks prior to registration. Note: Patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks",
            "criterions": [
                {
                    "exact_snippets": "Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1)",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coagulopathy in the absence of therapeutic anti-coagulation",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapeutic anti-coagulation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any hemorrhage/bleeding event > Grade 3 within 4 weeks prior to registration",
                    "criterion": "hemorrhage/bleeding event",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of uncontrollable allergic reactions to bevacizumab",
            "criterions": [
                {
                    "exact_snippets": "History of uncontrollable allergic reactions to bevacizumab",
                    "criterion": "allergic reactions to bevacizumab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "controllability",
                            "expected_value": "uncontrollable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction or unstable angina within 6 months",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina within 6 months",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of cerebrovascular accident (CVA) within 6 months",
            "criterions": [
                {
                    "exact_snippets": "History of cerebrovascular accident (CVA) within 6 months",
                    "criterion": "history of cerebrovascular accident (CVA)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess ≤ 6 months prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula ... ≤ 6 months prior to registration",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal perforation ... ≤ 6 months prior to registration",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intra-abdominal abscess ≤ 6 months prior to registration",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure ... ≤ 28 days prior to registration",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "open biopsy ... ≤ 28 days prior to registration",
                    "criterion": "open biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury ≤ 28 days prior to registration",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since injury",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent",
            "criterions": [
                {
                    "exact_snippets": "clinically significant medical disease or condition",
                    "criterion": "clinically significant medical disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on protocol adherence or ability to give informed consent (in the Investigator's opinion)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on protocol adherence or ability to give informed consent (in the Investigator's opinion)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on protocol adherence or ability to give informed consent (in the Investigator's opinion)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequately controlled hypertension (i.e., systolic blood pressure (SBP) > 160 mm Hg and/or diastolic blood pressure (DBP) > 90 mm Hg despite antihypertensive therapy)",
            "criterions": [
                {
                    "exact_snippets": "systolic blood pressure (SBP) > 160 mm Hg ... despite antihypertensive therapy",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "control despite antihypertensive therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure (DBP) > 90 mm Hg ... despite antihypertensive therapy",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "control despite antihypertensive therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Active wound, a serious or non-healing wound, an active ulcer or untreated bone fracture within the last two months.",
            "criterions": [
                {
                    "exact_snippets": "Active wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a serious or non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or healing status",
                            "expected_value": [
                                "serious",
                                "non-healing"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "an active ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture within the last two months",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Immunotherapy, chemotherapy, radiotherapy, or experimental therapy within one full cycle period before first dose of study drug (i.e., for lomustine 6 weeks, for temozolomide 4 weeks)",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy ... within one full cycle period before first dose of study drug",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... within one full cycle period before first dose of study drug (i.e., for lomustine 6 weeks, for temozolomide 4 weeks)",
                    "criterion": "chemotherapy (lomustine)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... within one full cycle period before first dose of study drug (i.e., for lomustine 6 weeks, for temozolomide 4 weeks)",
                    "criterion": "chemotherapy (temozolomide)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy ... within one full cycle period before first dose of study drug",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": "at least one full cycle period (duration not specified)"
                        }
                    ]
                },
                {
                    "exact_snippets": "experimental therapy within one full cycle period before first dose of study drug",
                    "criterion": "experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": "at least one full cycle period (duration not specified)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral APG-157, or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "Any life-threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "life-threatening illness, medical condition, or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the investigator's opinion, could compromise the subject's safety",
                    "criterion": "condition compromising subject's safety (per investigator's opinion)",
                    "requirements": [
                        {
                            "requirement_type": "risk to safety",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "interfere with the absorption or metabolism of oral APG-157",
                    "criterion": "condition interfering with absorption or metabolism of oral APG-157",
                    "requirements": [
                        {
                            "requirement_type": "interference with absorption or metabolism of APG-157",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "put the study outcomes at undue risk",
                    "criterion": "condition putting study outcomes at undue risk",
                    "requirements": [
                        {
                            "requirement_type": "risk to study outcomes",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}